Westend Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Westend Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	$37K	Buy	+1,000	New	+$39K	0.04%	72

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Westend Partners's TEVA Position: Q3 2013 in Review

Westend Partners opened a new position in Teva Pharmaceuticals (TEVA) in Q3 2013: 1,000 shares worth $37K. The stake represents 0.04% of the portfolio and ranks #72 among its holdings.

705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

Westend Partners held 1,000 shares of Teva Pharmaceuticals worth $37K as of Q3 2013.
Teva Pharmaceuticals was a new Westend Partners position in Q3 2013.
Teva Pharmaceuticals made up 0.04% of Westend Partners's portfolio in Q3 2013, its #72 holding.
705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on Westend Partners's 13F filing for Q3 2013, filed 13 Nov 2013.